Deal for Gleolan in the United States Medexus has acquired exclusive rights to commercialize Gleolan in the United States,
complementing Medexus’s existing rights to Gleolan in Canada
Gleolan is an optical imaging agent currently indicated in the United States in patients with glioma
as an adjunct for the visualization of malignant tissue or tumor tissue during surgery
Gleolan generated $3-4 million U.S. net sales in the fourth calendar quarter of 2021
TORONTO and CHICAGO, March 01, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that its U.S. subsidiary, Medexus Pharma (Medexus US), has acquired the exclusive right to commercialize Gleolan in the United States from NX Development Corp. (NXDC), the U.S. subsidiary of photonamic GmbH & Co. (Photonamic). This transaction extends Medexus’s strong relationship with Photonamic and complements Medexus’s existing commercialization rights to Gleolan in Canada, where Medexus recently launched the product. Using information provided by NXDC, Medexus estimates that Gleolan generated U.S. net sales of $3 million to $4 million in the fourth calendar quarter of 2021. Based on Medexus’s evaluation of Gleolan’s effectiveness, Medexus is confident in Gleolan’s prospects in both Canada and the United States, and expects strong sales and institutional uptake in both markets. Medexus and NXDC plan to work together closely to ensure a seamless transition for existing customers.